newsfilter
← Latest News
GlobeNewswire·

Kymera Therapeutics Appoints Felix J. Baker, Ph.D., as Chairman of the Board of Directors

  • Kymera Therapeutics appointed Felix J. Baker, PhD, as Chairman of the Board of Directors on June 24, 2026.
  • Bruce Booth, DPhil, succeeded as Chairman by Dr. Baker after serving in the role since co-founding the company in 2016.
  • Dr. Booth will remain on the board as an Independent Director following his transition out of the Chairmanship.
  • Dr. Baker previously served as Kymera's Lead Independent Director starting in 2024.
  • Dr. Baker is a Managing Member of Baker Brothers Investments, which he co-founded in 2000.
  • Dr. Baker holds a BS and PhD in Immunology from Stanford University and completed two years of medical school there.
  • Dr. Baker also serves on the boards of BeOne Medicines Ltd., Bicycle Therapeutics PLC, Kodiak Sciences, Inc., and Kiniksa Pharmaceuticals International, plc.
  • CEO Nello Mainolfi highlighted Dr. Baker's strategic insights in helping Kymera scale its oral degrader pipeline.
  • Kymera is a clinical-stage biotechnology company focused on targeted protein degradation (TPD) to develop oral small molecule degraders for immunological diseases.
  • The company was founded in 2016 and is recognized as one of Boston's top workplaces.